<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280575</url>
  </required_header>
  <id_info>
    <org_study_id>19HH5060</org_study_id>
    <nct_id>NCT04280575</nct_id>
  </id_info>
  <brief_title>Symptomatic Trial of Angina Assessment Prior to Revascularization</brief_title>
  <acronym>ORBITA-STAR</acronym>
  <official_title>Symptomatic Trial of Angina Assessment Prior to Revascularization: A Placebo-controlled Experiment on Symptoms in Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Basildon and Thurrock University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective of this research is to determine whether symptoms, induced by
      confirmed experimental ischaemia, can help us predict which patients will respond to PCI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo controlled similarity score during low pressure balloon occlusion of the coronary artery</measure>
    <time_frame>30 Days</time_frame>
    <description>Similarity Score (1-10) (Higher Score = Better Outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in angina symptom score</measure>
    <time_frame>30 Days</time_frame>
    <description>Fractional Change in Angina Frequency (0-1) (Lower Score = Better Outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in treadmill exercise time</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in treadmill time to chest pain</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina severity as assessed by Canadian Cardiovascular Society Class</measure>
    <time_frame>30 Days</time_frame>
    <description>Canadian Cardiovascular Society Class (0-IV) (Lower Score = Better Outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical limitation, angina stability, quality of life, angina frequency, freedom from angina as assessed with the Seattle Angina Questionnaire.</measure>
    <time_frame>30 Days</time_frame>
    <description>Seattle Angina Questionnaire, (Lower Score = Better Outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed with the EQ-5D-5L questionnaire</measure>
    <time_frame>30 Days</time_frame>
    <description>(Lower Score = Better Outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dobutamine stress echocardiography score</measure>
    <time_frame>30 Days</time_frame>
    <description>(Lower Score = Better Outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for anti-anginal medication introduction and uptitration</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety as assessed by the GAD-7 Score</measure>
    <time_frame>30 days</time_frame>
    <description>Generalised anxiety and depression - 7 Score. (Lower Score = Better Outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression as assessed by the PHQ-9 Score</measure>
    <time_frame>30 days</time_frame>
    <description>Patient Health Questionnaire - 9. (Lower Score = Better Outcome)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina, Stable</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Coronary artery stenting for stable angina</description>
    <other_name>PCI</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum troponin samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with single-vessel coronary artery disease with symptoms of stable
        angina
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Angina or angina-equivalent symptoms

          2. Anatomical evidence of a significant single vessel coronary stenosis on diagnostic
             coronary angiography indicating â‰¥ 70% stenosis

          3. Referred for percutaneous coronary intervention for treatment of stable angina

        Exclusion Criteria:

          1. Age younger than 18

          2. Age older than 85

          3. Recent acute coronary syndrome

          4. Multivessel coronary artery disease

          5. Previous coronary artery bypass graft surgery

          6. Significant left main stem coronary disease

          7. Chronic total occlusion in the target vessel

          8. Contraindication to percutaneous coronary intervention or drug-eluting stent
             implantation

          9. Contraindication to antiplatelet therapy

         10. Contraindication to adenosine infusion

         11. Severe valvular disease

         12. Severe LV systolic impairment

         13. Severe respiratory disease

         14. Life expectancy less than 2 years, pregnancy, unable to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rasha K Al-Lamee</last_name>
    <phone>+44 208 082 5109</phone>
    <email>r.al-lamee13@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher A Rajkumar</last_name>
    <phone>+44 208 082 5109</phone>
    <email>christopher.rajkumar07@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Essex Cardiothoracic Centre, Basildon and Thurrock University Hospitals NHS Trust</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald A Clesham</last_name>
      <email>gerald.clesham@meht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasha K Al-Lamee</last_name>
      <phone>+44 208 082 5109</phone>
      <email>r.al-lamee13@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

